Korro Bio (KRRO) Non-Current Deffered Revenue (2019 - 2026)

Korro Bio's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 26.59% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 26.59% YoY) and the FY2025 annual result came in at $7.8 million, up 32.53% from the prior year.
• Non-Current Deffered Revenue was $7.7 million for Q1 2026 at Korro Bio, down from $7.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $7.8 million in Q4 2025 and bottomed at $4.5 million in Q2 2025.
• A 3-year average of $6.4 million and a median of $6.0 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Peak annual rise in Non-Current Deffered Revenue reached 32.53% in 2025, while the deepest fall reached 38.45% in 2025.
• Korro Bio's Non-Current Deffered Revenue stood at $5.9 million in 2024, then soared by 32.53% to $7.8 million in 2025, then retreated by 2.28% to $7.7 million in 2026.
• Business Quant data shows KRRO's Non-Current Deffered Revenue at $7.7 million in Q1 2026, $7.8 million in Q4 2025, and $4.8 million in Q3 2025.